BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Di Minno MN, Iervolino S, Peluso R, Russolillo A, Lupoli R, Scarpa R, Di Minno G, Tarantino G. Hepatic steatosis and disease activity in subjects with psoriatic arthritis receiving tumor necrosis factor-α blockers. J Rheumatol. 2012;39:1042-1046. [PMID: 22422493 DOI: 10.3899/jrheum.111391] [Cited by in Crossref: 25] [Cited by in F6Publishing: 27] [Article Influence: 2.8] [Reference Citation Analysis]
Number Citing Articles
1 Husni ME. Comorbidities in Psoriatic Arthritis. Rheum Dis Clin North Am 2015;41:677-98. [PMID: 26476226 DOI: 10.1016/j.rdc.2015.07.008] [Cited by in Crossref: 78] [Cited by in F6Publishing: 40] [Article Influence: 13.0] [Reference Citation Analysis]
2 Pakchotanon R, Ye JY, Cook RJ, Chandran V, Gladman DD. Liver Abnormalities in Patients with Psoriatic Arthritis. J Rheumatol 2020;47:847-53. [PMID: 31615918 DOI: 10.3899/jrheum.181312] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
3 Font-Burgada J, Sun B, Karin M. Obesity and Cancer: The Oil that Feeds the Flame. Cell Metab. 2016;23:48-62. [PMID: 26771116 DOI: 10.1016/j.cmet.2015.12.015] [Cited by in Crossref: 197] [Cited by in F6Publishing: 160] [Article Influence: 39.4] [Reference Citation Analysis]
4 Tang KT, Dufour JF, Chen PH, Hernaez R, Hutfless S. Antitumour necrosis factor-α agents and development of new-onset cirrhosis or non-alcoholic fatty liver disease: a retrospective cohort. BMJ Open Gastroenterol 2020;7:e000349. [PMID: 32377366 DOI: 10.1136/bmjgast-2019-000349] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
5 Feagins LA, Flores A, Arriens C, Park C, Crook T, Reimold A, Brown G. Nonalcoholic fatty liver disease: a potential consequence of tumor necrosis factor-inhibitor therapy. Eur J Gastroenterol Hepatol. 2015;27:1154-1160. [PMID: 26148245 DOI: 10.1097/meg.0000000000000421] [Cited by in Crossref: 12] [Cited by in F6Publishing: 8] [Article Influence: 2.4] [Reference Citation Analysis]
6 Galíndez E, Carmona L. Is obesity in psoriatic arthritis associated with a poorer therapeutic response and more adverse effects of treatment with an anchor drug? Reumatol Clin 2016;12:307-12. [PMID: 26830438 DOI: 10.1016/j.reuma.2015.12.005] [Cited by in Crossref: 17] [Cited by in F6Publishing: 12] [Article Influence: 3.4] [Reference Citation Analysis]
7 Gentile M, Peluso R, Di Minno MND, Costa L, Caso F, de Simone B, Iannuzzo G, Scarpa R, Rubba P. Association between small dense LDL and sub-clinical atherosclerosis in patients with psoriatic arthritis. Clin Rheumatol 2016;35:2023-9. [PMID: 27411815 DOI: 10.1007/s10067-016-3344-4] [Cited by in Crossref: 14] [Cited by in F6Publishing: 14] [Article Influence: 2.8] [Reference Citation Analysis]
8 Barrea L, Macchia PE, Tarantino G, Di Somma C, Pane E, Balato N, Napolitano M, Colao A, Savastano S. Nutrition: a key environmental dietary factor in clinical severity and cardio-metabolic risk in psoriatic male patients evaluated by 7-day food-frequency questionnaire. J Transl Med 2015;13:303. [PMID: 26376719 DOI: 10.1186/s12967-015-0658-y] [Cited by in Crossref: 35] [Cited by in F6Publishing: 33] [Article Influence: 5.8] [Reference Citation Analysis]
9 Porta S, Otero-Losada M, Kölliker Frers RA, Cosentino V, Kerzberg E, Capani F. Adipokines, Cardiovascular Risk, and Therapeutic Management in Obesity and Psoriatic Arthritis. Front Immunol 2020;11:590749. [PMID: 33643281 DOI: 10.3389/fimmu.2020.590749] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
10 Ogdie A, Schwartzman S, Husni ME. Recognizing and managing comorbidities in psoriatic arthritis. Curr Opin Rheumatol 2015;27:118-26. [PMID: 25603040 DOI: 10.1097/BOR.0000000000000152] [Cited by in Crossref: 105] [Cited by in F6Publishing: 40] [Article Influence: 17.5] [Reference Citation Analysis]
11 Di Minno MN, Peluso R, Iervolino S, Lupoli R, Russolillo A, Tarantino G, Scarpa R. Hepatic steatosis, carotid plaques and achieving MDA in psoriatic arthritis patients starting TNF-α blockers treatment: a prospective study. Arthritis Res Ther 2012;14:R211. [PMID: 23036698 DOI: 10.1186/ar4049] [Cited by in Crossref: 25] [Cited by in F6Publishing: 21] [Article Influence: 2.8] [Reference Citation Analysis]
12 Di Minno MN, Russolillo A, Lupoli R, Ambrosino P, Di Minno A, Tarantino G. Omega-3 fatty acids for the treatment of non-alcoholic fatty liver disease. World J Gastroenterol 2012;18:5839-47. [PMID: 23139599 DOI: 10.3748/wjg.v18.i41.5839] [Cited by in CrossRef: 98] [Cited by in F6Publishing: 83] [Article Influence: 12.3] [Reference Citation Analysis]
13 Klujszo EH, Parcheta P, Witkowska AB, Krecisz B. Non-alcoholic fatty liver disease in patients with psoriasis: therapeutic implications. Postepy Dermatol Alergol 2020;37:468-74. [PMID: 32994765 DOI: 10.5114/ada.2019.83983] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
14 Ogdie A, Schwartzman S, Eder L, Maharaj AB, Zisman D, Raychaudhuri SP, Reddy SM, Husni E. Comprehensive Treatment of Psoriatic Arthritis: Managing Comorbidities and Extraarticular Manifestations. J Rheumatol 2014;41:2315-22. [DOI: 10.3899/jrheum.140882] [Cited by in Crossref: 46] [Cited by in F6Publishing: 31] [Article Influence: 6.6] [Reference Citation Analysis]
15 Biancone L, Annese V, Ardizzone S, Armuzzi A, Calabrese E, Caprioli F, Castiglione F, Comberlato M, Cottone M, Danese S, Daperno M, D’incà R, Frieri G, Fries W, Gionchetti P, Kohn A, Latella G, Milla M, Orlando A, Papi C, Petruzziello C, Riegler G, Rizzello F, Saibeni S, Scribano ML, Vecchi M, Vernia P, Meucci G, Aratari A, Bossa F, Cappello M, Cassinotti A, Chiriatti A, Fiorino G, Formica V, Guidi L, Losco A, Mocciaro F, Onali S, Pastorelli L, Pica R, Principi M, Renna S, Ricci C, Rispo A, Rogai F, Sarmati L, Scaldaferri F, Spina L, Tambasco R, Testa A, Viscido A. Safety of treatments for inflammatory bowel disease: Clinical practice guidelines of the Italian Group for the Study of Inflammatory Bowel Disease (IG-IBD). Digestive and Liver Disease 2017;49:338-58. [DOI: 10.1016/j.dld.2017.01.141] [Cited by in Crossref: 26] [Cited by in F6Publishing: 21] [Article Influence: 6.5] [Reference Citation Analysis]
16 Di Minno MND, Iervolino S, Peluso R, Di Minno A, Ambrosino P, Scarpa R; the CaRRDs Study Group. Hemostatic and Fibrinolytic Changes Are Related to Inflammatory Conditions in Patients with Psoriatic Arthritis — Effect of Different Treatments. J Rheumatol 2014;41:714-22. [DOI: 10.3899/jrheum.130850] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 1.3] [Reference Citation Analysis]
17 Di Minno MND, Iervolino S, Zincarelli C, Lupoli R, Ambrosino P, Pizzicato P, Di Minno A, Pappone N, Peluso R. Cardiovascular effects of Etanercept in patients with psoriatic arthritis: evidence from the cardiovascular risk in rheumatic diseases database. Expert Opinion on Drug Safety 2015;14:1905-13. [DOI: 10.1517/14740338.2015.1111870] [Cited by in Crossref: 9] [Cited by in F6Publishing: 6] [Article Influence: 1.5] [Reference Citation Analysis]
18 Di Minno MN, Ambrosino P, Peluso R, Di Minno A, Lupoli R, Dentali F; CaRRDs Study Group. Lipid profile changes in patients with rheumatic diseases receiving a treatment with TNF-α blockers: a meta-analysis of prospective studies. Ann Med 2014;46:73-83. [PMID: 24460516 DOI: 10.3109/07853890.2013.874661] [Cited by in Crossref: 21] [Cited by in F6Publishing: 19] [Article Influence: 3.0] [Reference Citation Analysis]
19 Finelli C, Tarantino G. What is the role of adiponectin in obesity related non-alcoholic fatty liver disease? World J Gastroenterol 2013;19:802-12. [PMID: 23430039 DOI: 10.3748/wjg.v19.i6.802] [Cited by in CrossRef: 101] [Cited by in F6Publishing: 94] [Article Influence: 12.6] [Reference Citation Analysis]
20 Russolillo A, Iervolino S, Peluso R, Lupoli R, Di Minno A, Pappone N, Di Minno MND. Obesity and psoriatic arthritis: from pathogenesis to clinical outcome and management. Rheumatology 2012;52:62-7. [DOI: 10.1093/rheumatology/kes242] [Cited by in Crossref: 74] [Cited by in F6Publishing: 57] [Article Influence: 8.2] [Reference Citation Analysis]
21 Di Minno MN, Peluso R, Iervolino S, Russolillo A, Lupoli R, Scarpa R; CaRRDs Study Group. Weight loss and achievement of minimal disease activity in patients with psoriatic arthritis starting treatment with tumour necrosis factor α blockers. Ann Rheum Dis 2014;73:1157-62. [PMID: 23771989 DOI: 10.1136/annrheumdis-2012-202812] [Cited by in Crossref: 119] [Cited by in F6Publishing: 76] [Article Influence: 14.9] [Reference Citation Analysis]
22 Lupoli R, Pizzicato P, Scalera A, Ambrosino P, Amato M, Peluso R, Di Minno MN. Impact of body weight on the achievement of minimal disease activity in patients with rheumatic diseases: a systematic review and meta-analysis. Arthritis Res Ther 2016;18:297. [PMID: 27964760 DOI: 10.1186/s13075-016-1194-8] [Cited by in Crossref: 26] [Cited by in F6Publishing: 19] [Article Influence: 5.2] [Reference Citation Analysis]
23 Shah P, Sundaram V, Björnsson E. Biologic and Checkpoint Inhibitor-Induced Liver Injury: A Systematic Literature Review. Hepatol Commun 2020;4:172-84. [PMID: 32025603 DOI: 10.1002/hep4.1465] [Cited by in Crossref: 10] [Cited by in F6Publishing: 6] [Article Influence: 10.0] [Reference Citation Analysis]
24 Peluso R, Caso F, Tasso M, Ambrosino P, Dario Di Minno MN, Lupoli R, Criscuolo L, Caso P, Ursini F, Puente AD, Scarpa R, Costa On Behalf Of CaRRDs Study Group L. Cardiovascular Risk Markers and Major Adverse Cardiovascular Events in Psoriatic Arthritis Patients. Rev Recent Clin Trials 2018;13:199-209. [PMID: 29542417 DOI: 10.2174/1574887113666180314105511] [Cited by in Crossref: 8] [Cited by in F6Publishing: 4] [Article Influence: 2.7] [Reference Citation Analysis]
25 Peluso R, Di Minno MN, Iervolino S, Manguso F, Tramontano G, Ambrosino P, Esposito C, Scalera A, Castiglione F, Scarpa R. Enteropathic spondyloarthritis: from diagnosis to treatment. Clin Dev Immunol. 2013;2013:631408. [PMID: 23690825 DOI: 10.1155/2013/631408] [Cited by in Crossref: 41] [Cited by in F6Publishing: 20] [Article Influence: 5.1] [Reference Citation Analysis]
26 di Minno MND, Peluso R, Iervolino S, Lupoli R, Russolillo A, Scarpa R, di Minno G. Obesity and the prediction of minimal disease activity: A prospective study in psoriatic arthritis. Arthritis Care Res 2013;65:141-7. [DOI: 10.1002/acr.21711] [Cited by in Crossref: 103] [Cited by in F6Publishing: 80] [Article Influence: 11.4] [Reference Citation Analysis]